Hypertension
Supplement protects against thiazide-related hyperglycemia in randomized trial
KMgCit outperformed KCl, the common form of K supplement used in clinical practice, in preventing TD-induced hyperglycemia. Use of KMgCit may improve tolerability and CV safety in patients with hypertension treated with TDs.
- This double-blind, randomized controlled trial, which included 60 patients (mean age, 59 years; 30% Black) with hypertension but not diabetes, compared the effects of KCl vs. KMgCit during chlorthalidone treatment. Each patient received chlorthalidone alone for 3 weeks before randomization. Primary end point was the change in fasting plasma glucose after 16 weeks of KCl or KMgCit supplementation compared with glucose levels during chlorthalidone therapy alone.
- Use of chlorthalidone alone was associated with a significant rise in fasting plasma glucose, and a significant fall in serum K, serum Mg, and 24-hour urinary citrate excretion (all P<0.05). The addition of KMgCit attenuated the rise in fasting plasma glucose by 7.9 mg/dL. No such attenuation was observed with KCl.
Source:
Vongpatanasin W, et al. (2023, October 17). Hypertension. Potassium Magnesium Citrate Is Superior to Potassium Chloride in Reversing Metabolic Side Effects of Chlorthalidone. https://pubmed.ncbi.nlm.nih.gov/37846572/